Parsons James T. 4

What Happened
James T. Parsons, a director of Oncolytics Biotech Inc. (ONCY), was granted an award on June 1, 2026, covering 30,000 shares (reported as a derivative acquisition). The filing shows $0 cash paid at grant; the exercise price for the options equals the issuer's Nasdaq closing price on the grant date, so the grant had no intrinsic value at issuance.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (timely filing).
• Reported transaction type/code: A (Award/Grant of a derivative instrument).
• Amount granted: 30,000 option shares; reported acquisition price: $0.00 (derivative).
• Exercise price: equal to Nasdaq closing price on 2026-06-01 (footnote F1).
• Vesting: vests in three equal annual installments, first vesting on 2027-06-01, contingent on continued service (footnote F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, or a cashless exercise in this filing.

Context
This disclosure documents a standard director compensation grant (options) rather than an open-market buy or sale. Options awarded typically vest over time and do not represent immediate cash value unless the stock price rises above the exercise price and the options are later exercised and/or sold.